I was scanning my email this morning and saw an article by Joel Wallace and Tara L. Kurtis with The National Law Review titled ‘U.S. Pharmaceutical and Biologics Industries Could See Steep Potential Consequences from Texas Judge’s ACA Decision.‘
The article was written to promote how the ruling will impact U.S. pharmaceutical and biologics industries because “Judge Reed O’Connor (United States District Court for the Northern District of Texas) found the individual mandate of the Affordable Care Act (ACA) – and therefore the entire act – unconstitutional.”
A little history
The Affordable Care Act (ACA), aka The Patient Protection and Affordable Care Act (PPACA) 2010 HR3590 (Public Law 111–148) aka Obamacare aka program reform for the US (Health and Human Services and other Government programs). The briefest explanation of the ACA is that it is supposed to be about access to affordable healthcare for all Americans. For now we are in wait and see mode as Judge O’Connor did not issue a court order (injunction).
The pharmaceutical industry has a huge stake in this decision and so do millions of Americans who may lose prescription drug coverage. … Below are the Ten Titles of the PPACA.
- Title I Quality, affordable health care for all Americans
- Title II The role of public programs
- Title III Improving the quality and efficiency of healthcare
- Title IV Preventing chronic disease and improving public health
- Title V Health care workforce
- Title VI Transparency and program integrity
- Title VII Improving access to innovative medical therapies
- Title VIII Community living assistance services and supports
- Title IX Revenue Provisions
- Title X Reauthorization of the Indian Health Care Improvement Act
What are your thoughts on this?